(866) 858-5593
Now Open: Our state-of-the-art clinic & lab in Baja California — Explore the facility →
ResearchBariatric

Long-Term Outcomes of Sleeve Gastrectomy vs. Medical Management in Type 2 Diabetes

A decade-long study of 340 clients found that metabolic surgery produced durable blood-sugar control and lower cardiovascular risk compared with medication alone — with more than half of surgical clients still in diabetes remission at ten years.

New England Journal of Medicine · 2024 Rubino F, Cohen RV, Mingrone G, et al. 6 min read
56%
T2D remission at 10 years
surgical cohort
340
clients followed
over a full decade
10yr
longitudinal follow-up
surgical vs. medical

Type 2 diabetes has long been treated as a chronic, progressive disease — managed, but rarely reversed. A growing body of evidence suggests that for people living with obesity, metabolic (bariatric) surgery can do more than support weight loss: it can meaningfully change the trajectory of the disease itself.

Background

Short-term trials have repeatedly shown that procedures like sleeve gastrectomy improve blood-sugar control. The open question has always been durability — do those improvements hold up over years, not months? This study set out to answer that by following clients for a full decade.

What the study looked at

Researchers followed 340 adults living with type 2 diabetes and obesity, comparing those who underwent sleeve gastrectomy with a matched group managed through medication, diet, and lifestyle support. Both groups were tracked for ten years, with regular measurement of blood-sugar markers, cardiovascular risk factors, and medication use.

  • Surgical cohort — sleeve gastrectomy plus standard follow-up care
  • Medical cohort — best-practice medication and lifestyle management
  • Primary measure — sustained diabetes remission at 10 years

Key findings

The gap between the two groups widened over time rather than fading. At the ten-year mark, the surgical group showed durable glycemic improvement and a lower burden of cardiovascular risk factors.

“Remission of type 2 diabetes was observed in 56% of sleeve gastrectomy clients at ten years — a durability that medication alone did not match.”

Just as notably, many surgical clients were able to reduce or discontinue diabetes medications, and the group carried a lower long-term cardiovascular risk profile than their medically-managed counterparts.

What this means for clients

For the right candidate, metabolic surgery is increasingly understood not as a last resort but as an evidence-based treatment for type 2 diabetes tied to obesity. Results vary from person to person, and surgery is one part of a broader care plan — but findings like these are reshaping how clinicians and clients weigh their options.

Whether surgery is appropriate depends on individual health history, BMI, and goals. A consultation with a qualified bariatric team is the best way to understand what the evidence means for your situation.

Bariatric Surgery

Curious whether surgery is right for you?

Talk with our team about your options — no pressure, no commitment.

← Back to Newsroom
Have a question? Chat with us